Lipoprotein(a): biochemistry and genetics.

Lipoprotein(a): biochemistry and genetics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lipoprotein(a): biochemistry and genetics. Abstract Text:

R A Hegele,

Lipoprotein(a): biochemistry and genetics. Publishing Authors By Initials

RA Hegele,

For similar lipids: lipoproteins: lipoproteins, ldl research abstracts see: lipids: lipoproteins: lipoproteins, ldl research

PUBMED ID PMID:

MEDLINE DATE:

Lipoprotein(a): biochemistry and genetics. Journal Published:

PUBLICATION TYPE: Review

Journal: The Canadian journal of cardiology

VOLUME: 8

Page Numbers: 893-5

Journal Abbreviation:

ISSN: 0828-282X

DAY: 9

MONTH: Nov

YEAR: 1992

Lipoprotein(a): biochemistry and genetics. Information

Number of References: 18

LANGUAGE: eng

NlmUniqueID: 8510280

Lipoprotein(a): biochemistry and genetics. Keywords Mesh Terms:

KEYWORDS: Lipoproteins, LDL

MESH TERMS: biosynthesis

Chemical & Substance for Abstract: Lipoprotein(a): biochemistry and genetics. Information

Substance Name: Apoprotein(a)

Registry Number: EC 3.4.21.-

Grant and Affiliation Information for Lipoprotein(a): biochemistry and genetics.

AFFILIATION: University of Toronto, Ontario, Canada.

Country: CANADA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lipoproteina: biochemistry and genetics Related Publications

• A Glimpse at HDL-based Therapy for Atherosclerosis.
• Abetalipoproteinemia: two case reports and literature review.
• Adaptation to visuomotor rotations in younger and older adults.
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
• Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.
• Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population.
• Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
• Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
• Emerging antidyslipidemic drugs.
• GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
• Gene-environment interactions in atherosclerosis.
• Gene-environment interactions in atherosclerosis: animal models.
• Genetic determinants of plasma lipoproteins.
• Genetics of metabolic syndrome.
• Genetics of metabolic syndrome: is there a role for phenomics?
• HIV-associated dyslipidaemia: pathogenesis and treatment.
• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
• Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism.
• Is raising HDL a futile strategy for atheroprotection?
• Lipoprotein (a): an emerging risk factor for atherosclerosis.
• Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
• Lipoprotein(a) and fibrinolysis.
• Lipoprotein(a): biochemistry and genetics.
• Microsomal triglyceride transfer protein inhibition-friend or foe?
• Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum.
• Phenomics, lamin A/C, and metabolic disease.
• Single nucleotide polymorphisms of the fukutin gene.
• Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
• The failure of torcetrapib: what have we learned?